THUNDER BAY, ON (May 28,2014) – XLV Diagnostics Inc., a MaRS Innovation (MI) start-up company based in Thunder Bay and specializing in low-cost, next-generation digital mammography machines, has closed a…
In a January 24, 2014 Biotechnology Focus cover article, author Shawn Lawrence discusses MaRS Innovation President and CEO Dr. Raphael (Rafi) Hofstein‘s recent visit to learn more of the emerging science and technology markets in Singapore and Japan.
The trip allowed Hofstein to discuss current MI projects, specifically start-ups XLV Diagnostics Inc. and DVLR Therapeutics Inc., whose products could benefit from Singapore’s proximity to medical technology markets in India and China.
TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.
Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.
XLV’s solution has the potential to provide image quality that equals or surpasses that which is currently in use, making images easy to analyze, manipulate and transfer much like digital photographs. It will also substantially decrease the cost of digital mammography machines.
Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions
MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for its 16 member institutions.
The Networks of Centres of Excellence (NCE) has recognized the increasing strength of this novel partnership by awarding MI $14.95 million in funding through the Centres of Excellence for Commercialization and Research (CECR) program.
Dr. John Rowlands’ X-ray Light Valve technology among the first TBRRI patents that MaRS Innovation will bring to market January 26, 2011 (Thunder Bay, ON) – Today, MaRS Innovation welcomes…